Last updated: 11/03/2018 13:03:29

Epidemiological, observational and post marketing study of Rotarix™ in children with severe gastroenteritis in Belgium

GSK study ID
112560
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Epidemiological, observational, post marketing study of the genetic stability of GSK Biologicals’ rotavirus vaccine (Rotarix™) in children <5 years of age diagnosed with severe gastroenteritis, in Belgium
Trial description: The main aim of this study is to investigate cases of rotavirus gastroenteritis in Belgian children with opportunity to receive Rotarix™ to monitor the potential occurrence of genetic drifts (point mutations) in the vaccine strain and the occurrence of genetic shifts (re-assortments) between vaccine and naturally circulating wild-type strains in Belgium population after the introduction of Rotarix™. The study will also detect if there is any alteration in rotavirus pathogenicity conferred by re-assortment and if the mutated vaccine strain is still efficacious in preventing rotavirus gastroenteritis.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:

Occurrence of rotavirus gastroenteritis among children hospitalized with acute gastroenteritis who have had opportunity to receive Rotarix™.

Timeframe: Over a three-year period

Occurrence of G1 and/or P[8] rotavirus gastroenteritis among children hospitalized with rotavirus gastroenteritis

Timeframe: Over a three-year period

Occurrence of vaccine-derived G1 and/or P[8] encoding gene segments among children hospitalized with rotavirus gastroenteritis due to G1 and/or P[8] strains

Timeframe: Over a three-year period

Occurrence of mutated vaccine strains and re-assortments among hospitalized children with vaccine-derived G1 and/or P[8] encoding gene segments

Timeframe: Over a three-year period

Clinical characteristics of hospitalized children with vaccine-derived G1 and/or P[8] encoding gene segments, and with vaccine-derived re-assortant strains and vaccine-derived mutated strains

Timeframe: Over a three-year period

Occurrence of co-infections due to other common viral intestinal pathogens (norovirus, astrovirus, adenovirus) among hospitalized children with rotavirus gastroenteritis

Timeframe: Over a three-year period

Epidemiological characteristics of hospitalized children with vaccine-derived G1 and/or P(8) encoding gene segments, and with vaccine-derived re-assortant strains and vaccine-derived mutated strains

Timeframe: Over a three-year period

Secondary outcomes:
Not applicable
Interventions:
  • Procedure/surgery: Stool samples
  • Enrollment:
    72
    Primary completion date:
    2012-20-06
    Observational study model:
    Case-Only
    Time perspective:
    Other
    Clinical publications:
    Not applicable
    Medical condition
    Infections, Rotavirus
    Product
    SB444563
    Collaborators
    Not applicable
    Study date(s)
    March 2011 to June 2012
    Type
    Observational
    Phase
    Not applicable

    Participation criteria

    Sex
    Female & Male
    Age
    14 weeks - 5 years
    Accepts healthy volunteers
    No
    • Phase I:
    • Vaccinated and unvaccinated confirmed G1 and/or P[8] rotavirus gastroenteritis cases from the RotaBel study.
    • Child in care.

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Genk, Belgium, 3600
    Status
    Study Complete
    Location
    GSK Investigational Site
    Kortrijk, Belgium, 8500
    Status
    Study Complete
    Location
    GSK Investigational Site
    Roeselaere, Belgium, 8800
    Status
    Study Complete
    Location
    GSK Investigational Site
    Bruxelles, Belgium, 1070
    Status
    Terminated/Withdrawn
    Location
    GSK Investigational Site
    Sint-Truiden, Belgium, 3800
    Status
    Study Complete
    Location
    GSK Investigational Site
    Wilrijk, Belgium, 2610
    Status
    Study Complete
    Showing 1 - 6 of 11 Results

    Study documents

    Scientific result summary
    Available language(s): English

    If you wish to request for full study report, please contact - [email protected]

    Results overview

    Refer to study documents

    Recruitment status
    Study complete
    Actual primary completion date
    2012-20-06
    Actual study completion date
    2012-20-06

    Plain language summaries

    Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.

    Additional information about the trial

    Not applicable
    Participate in clinical trial
    Access to clinical trial data by researchers
    Visit website